伊沙佐米显著延长高危复发/难治性骨髓瘤患者的无进展生存期
TOURMALINE-MM1 三期研究预设分析,按荧光原位杂交细胞遗传学风险分层,比较伊沙佐米-来那度胺-地塞米松(IRd)与安慰剂-来那度胺-地塞米松(安慰剂-Rd)在复发/难治性多发性骨髓瘤中的疗效与安全性。722 例随机患者中 552 例有细胞遗传学结果,137 例(25%)高危,172 例(32%)单纯 1q21 扩增。高危组 IRd 较安慰剂-Rd 改善无进展生存期(HR 0.543,95%CI 0.321-0.918,P=0.021;中位 21.4 对 9.7 个月),标危组亦改善(HR 0.640,95%CI 0.462-0.888,P=0.007;中位 20.6 对 15.6 个月)。
要点
- 高危细胞遗传学组 IRd 较安慰剂-Rd 中位无进展生存期 21.4 对 9.7 个月,HR 0.543。
- 标危细胞遗传学组 IRd 较安慰剂-Rd 中位无进展生存期 20.6 对 15.6 个月,HR 0.640。
- del(17p) 亚组 HR 0.596(95%CI 0.286-1.243),1q21 扩增组 HR 0.781(95%CI 0.492-1.240)。
核心结论
- 在复发和/或难治性多发性骨髓瘤患者中,IRd 较高危和标危细胞遗传学组均显示较安慰剂-Rd 改善无进展生存期,并改善高危细胞遗传学异常相关的较差无进展生存期。
研究设计与样本
- TOURMALINE-MM1 三期研究预设分析,按荧光原位杂交评估的细胞遗传学风险分层,比较 IRd 与安慰剂-Rd 的疗效和安全性。
- 722 例随机患者中 552 例有细胞遗传学结果,137 例(25%)有高危细胞遗传学异常,172 例(32%)为单纯 1q21 扩增。
- 高危细胞遗传学异常定义为 del(17p)、t(4;14) 和/或 t(14;16),并额外评估 1q21 扩增。
主要发现
- 高危细胞遗传学组:IRd 较安慰剂-Rd 的无进展生存期 HR 为 0.543(95%CI 0.321-0.918,P=0.021),中位无进展生存期 21.4 对 9.7 个月。
- 标危细胞遗传学组:IRd 较安慰剂-Rd 的无进展生存期 HR 为 0.640(95%CI 0.462-0.888,P=0.007),中位无进展生存期 20.6 对 15.6 个月。
- del(17p) 亚组:IRd 较安慰剂-Rd 的无进展生存期 HR 为 0.596(95%CI 0.286-1.243)。
- 1q21 扩增组:IRd 较安慰剂-Rd 的无进展生存期 HR 为 0.781(95%CI 0.492-1.240)。
- 扩展高危组(高危细胞遗传学异常和/或 1q21 扩增):IRd 较安慰剂-Rd 的无进展生存期 HR 为 0.664(95%CI 0.474-0.928)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Certain cytogenetic abnormalities are known to adversely impact outcomes in patients with multiple myeloma (MM). The phase 3 TOURMALINE-MM1 study demonstrated a significant improvement in progression-free survival (PFS) with ixazomib-lenalidomide-dexamethasone (IRd) compared with placebo-lenalidomide-dexamethasone (placebo-Rd). This preplanned analysis assessed the efficacy and safety of IRd vs placebo-Rd according to cytogenetic risk, as assessed using fluorescence in situ hybridization. High-risk cytogenetic abnormalities were defined as del(17p), t(4;14), and/or t(14;16); additionally, patients were assessed for 1q21 amplification. Of 722 randomized patients, 552 had cytogenetic results; 137 (25%) had high-risk cytogenetic abnormalities and 172 (32%) had 1q21 amplification alone. PFS was improved with IRd vs placebo-Rd in both high-risk and standard-risk cytogenetics subgroups: in high-risk patients, the hazard ratio (HR) was 0.543 (95% confidence interval [CI], 0.321-0.918; P = .021), with median PFS of 21.4 vs 9.7 months; in standard-risk patients, HR was 0.640 (95% CI, 0.462-0.888; P = .007), with median PFS of 20.6 vs 15.6 months. This PFS benefit was consistent across subgroups with individual high-risk cytogenetic abnormalities, including patients with del(17p) (HR, 0.596; 95% CI, 0.286-1.243). PFS was also longer with IRd vs placebo-Rd in patients with 1q21 amplification (HR, 0.781; 95% CI, 0.492-1.240), and in the "expanded high-risk" group, defined as those with high-risk cytogenetic abnormalities and/or 1q21 amplification (HR, 0.664; 95% CI, 0.474-0.928). IRd demonstrated substantial benefit compared with placebo-Rd in relapsed and/or refractory MM (RRMM) patients with high-risk and standard-risk cytogenetics, and improves the poor PFS associated with high-risk cytogenetic abnormalities. This trial was registered at www.clinicaltrials.gov as #NCT01564537.
引用
- Avet-Loiseau H, Bahlis NJ, Chng WJ, et al. Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. Blood. 2017. PMID: 29054911. doi:10.1182/blood-2017-06-791228
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。